Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
Status: | Recruiting |
---|---|
Conditions: | Cancer, Neurology |
Therapuetic Areas: | Neurology, Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 11/18/2012 |
Start Date: | November 2005 |
Auditory and Vestibular Function Evaluation in Patients With Solid Tumors Treated With Oxaliplatin-Containing Chemotherapy
RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral
neuropathy may improve the ability to plan effective treatment for patients receiving
oxaliplatin for solid tumors.
PURPOSE: This clinical trial is studying hearing loss and dizziness in patients receiving
oxaliplatin for solid tumors.
OBJECTIVES:
- Define the prevalence of audiometrically detectable hearing loss in patients with solid
tumors treated with oxaliplatin.
- Describe the association of chemotherapy-induced peripheral neuropathy (CIPN) and
audiometrically detectable hearing loss in these patients.
- Describe the association of CIPN and patient self-reported scales including, Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap
Inventory.
OUTLINE: This is an exploratory study.
Patients will complete three self-reported questionnaires including the Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory.
Patients will also be asked a series of questions regarding symptoms or complaints about
hearing changes, tinnitus, and dizziness that they may have experienced prior to, during,
and after completion of chemotherapy. Patients will also undergo a hearing test.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Diagnosis of solid tumor
- Received an oxaliplatin-containing chemotherapy regimen within the past 15
months* NOTE: *If oxaliplatin was omitted from the patient's most recent
chemotherapy regimen due to ototoxicity, the patient is still eligible for
participation in this study
- No known CNS metastases
PATIENT CHARACTERISTICS:
- No history of spinal injuries
- ECOG performance status 0-3
- No history of chronic renal failure
- No known HIV/AIDS
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
2
sites
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center We all know...
Click here to add this to my saved trials